ライフサイエンスコーパス: atrial

1 nd tissue properties promotes the genesis of atrial action potential (AP) alternans and conduction al

2 Atrial action potential (AP) morphology was altered in A

3 Cardiac sodium channel expression, I(Na) and atrial action potential duration were reduced and potass

4 With earlier PHCs, the degree of atrial advancement was equal or greater than the PHC pre

5 m underlying the increased susceptibility to atrial alternans in HF remains incompletely elucidated.

6 ical remodelling increased susceptibility to atrial alternans mainly due to the increased sarcoplasmi

7 or phenomena observed in experiments on both atrial and ventricular cardiac cells.

8 ce is an important trigger and substrate for atrial and ventricular proarrhythmia.

9 Atrial and ventricular sensing, lead impedance, and capt

10 viable, but a gene dosage-dependent drop in atrial ANP and BNP content occurred.

11 or cross-sectional study and collected right atrial appendage biopsies.

12 on coagulation system activation after left atrial appendage closure (LAAC) remains unknown.

13 (Left Atrial Appendage Closure vs. Novel Anticoagulation Agent

14 Left Atrial Appendage Closure vs. Novel Anticoagulation Agent

15 or patient's self-management [PSM] and left atrial appendage closure) are based on the concept of co

16 ure (mitral and tricuspid valve repair, left atrial appendage closure, and paravalvular leak closure)

17 ricular tachycardia ablation and Lariat left atrial appendage exclusion.

18 Left atrial appendage occlusion (LAAO) to prevent stroke in p

19 trials are addressing the usefulness of left atrial appendage occlusion in both primary and secondary

20 e first bifurcation and thrombus in the left atrial appendage.

21 area, vena contracta, color Doppler jet/left atrial area, left atrial volume index, left ventricular

22 ation of distal CS to LA connections reduced atrial arrhythmia recurrences compared with standard pul

23 ean follow-up of 170+/-22 days, there were 7 atrial arrhythmia recurrences in the standard group and

24 better among participants without documented atrial arrhythmia recurrences.

25 There were no differences in post LVAD atrial arrhythmias (AA) (Adjusted OR = 0.45 [0.18-1.06],

26 argue that it may explain the propensity for atrial arrhythmias in HF.

27 in PV isolation, and freedom from recurrent atrial arrhythmias.

28 ular components, and ultrastructure) in left atrial biopsies from 121 patients with persistent/long-l

29 Isolated atrial cardiomyocytes tachypaced at 3 Hz for 24 hours mi

30 Atrial cardiomyocytes were isolated from control and AF

31 d patch-clamp) and [Ca(2+)](i)-recordings in atrial cardiomyocytes, along with protein-expression lev

32 odels of MYL4 (myosin light chain 4)-related atrial cardiomyopathy.

33 om MYL4-/- human embryonic stem cell derived atrial cells demonstrated increased phospho-Cx43, which

34 pokalemia was only observed in a minority of atrial cells that were observed to contain t-tubules.

35 en early afterdepolarizations in untubulated atrial cells were enabled by membrane hyperpolarization

36 hypothesized that HF-induced remodelling of atrial cellular and tissue properties promotes the genes

37 Etv1(f/f)Mlc2a(Cre/+) mice displayed atrial conduction disease and arrhythmias.

38 on with increased P-wave duration and slowed atrial conduction velocity.

39 se in peak velocity flow in late diastole by atrial contraction (MV A Peak) indicating poorer left at

40 tio, 0.35 [95% CI, 0.16-0.79], P=0.01), left atrial diameter (odds ratio, 0.52 per 1 cm increase [95%

41 icular posterior wall diameter z score, left atrial diameter z score, peak left ventricular outflow t

42 a clinically relevant entity, defined as any atrial dysfunction causing impaired heart performance, s

43 Atrial dysfunction has been widely considered a marker o

44 underlying AF prevention was prolongation of atrial effective refractory periods, at least in part at

45 mouse models and explore the role of ETV1 in atrial electrical and structural remodeling.

46 urther analysis demonstrated that HF-induced atrial electrical remodelling increased susceptibility t

47 We performed panoramic recording of bi-atrial electrical signals in AF.

48 The left atrial end-systolic volume index (LAESVI) is a predictor

49 Here, we propose the term atrial failure as a clinically relevant entity, defined

50 c slices from 358 patients with nonrecurrent atrial fibrillation (1-3 mm interspace per slice, 20-200

51 %), previous heart failure (10% versus 19%), atrial fibrillation (6% versus 10%), and chronic obstruc

52 CLOSE-guided atrial fibrillation (AF) ablation is based on contiguous

53 rform transesophageal echocardiograms before atrial fibrillation (AF) ablation procedures in patients

54 Atrial fibrillation (AF) adversely impacts health-relate

55 2Y12 inhibitor) in patients with nonvalvular atrial fibrillation (AF) after percutaneous coronary int

56 Atrial fibrillation (AF) and atrial flutter (AFL) are as

57 Obesity is an independent risk factor for atrial fibrillation (AF) and is associated with a higher

58 ic diseases, the incidence and prevalence of atrial fibrillation (AF) are rising, justifying the term

59 Catheter ablation of persistent atrial fibrillation (AF) has limited success.

60 Scientific research on atrial fibrosis in atrial fibrillation (AF) has mainly focused on quantitat

61 ischaemic and haemorrhagic complications in atrial fibrillation (AF) have been studied, but there ar

62 It is difficult to noninvasively phenotype atrial fibrillation (AF) in a way that reflects clinical

63 the only anti-arrhythmic agents approved for atrial fibrillation (AF) in patients with reduced left v

64 The optimal timing of catheter ablation for atrial fibrillation (AF) in reference to the time of dia

65 Growing prevalence of atrial fibrillation (AF) in the ageing population and it

66 Atrial fibrillation (AF) is a highly prevalent cardiac a

67 Atrial fibrillation (AF) is associated with a risk of is

68 A very late recurrence (VLR) of atrial fibrillation (AF) is considered present when the

69 n with direct oral anticoagulants (DOACs) in atrial fibrillation (AF) is dependent on adherence and p

70 Susceptibility to atrial fibrillation (AF) is determined by well-recognize

71 The incidence of atrial fibrillation (AF) is higher in patients with diab

72 Atrial fibrillation (AF) is the most common clinical arr

73 Atrial fibrillation (AF) is the most common sustained ca

74 Emerging evidence suggests that atrial fibrillation (AF) may be associated with an incre

75 protein biomarkers associated with incident atrial fibrillation (AF) may improve the understanding o

76 Atrial fibrillation (AF) may occur after an acute precip

77 Atrial fibrillation (AF) often arises from structural ab

78 umulation associates with the progression of atrial fibrillation (AF) pathology and adversely affects

79 Asthma and atrial fibrillation (AF) share an underlying inflammator

80 ve a lower prevalence of clinically detected atrial fibrillation (AF) than whites, despite a higher p

81 lation) trial randomized 2,204 patients with atrial fibrillation (AF) to catheter ablation or drug th

82 for persistent and long-standing persistent atrial fibrillation (AF) treatment led to the developmen

83 ed with vast data sources, the management of atrial fibrillation (AF), a common chronic disease with

84 e, obesity, tobacco use, hypertension (HTN), atrial fibrillation (AF), and chronic obstructive pulmon

85 fective treatment strategy for patients with atrial fibrillation (AF), but many experience AF recurre

86 ed obesity as an independent risk factor for atrial fibrillation (AF), but the underlying pathophysio

87 mic heart disease (IHD), heart failure (HF), atrial fibrillation (AF), stroke, peripheral artery dise

88 ered over a 100 genetic loci associated with atrial fibrillation (AF), the most common arrhythmia.

89 Atrial fibrillation (AF), the most common sustained card

90 ied hundreds of genetic loci associated with atrial fibrillation (AF).

91 increasingly used treatment for symptomatic atrial fibrillation (AF).

92 in several well-characterized goat models of atrial fibrillation (AF).

93 and bleeding in a cohort with cirrhosis and atrial fibrillation (AF).

94 reflex/functional bradyarrhythmias and vagal atrial fibrillation (AF).

95 Ablation is a widely used therapy for atrial fibrillation (AF); however, arrhythmia recurrence

96 y end points were freedom from recurrence of atrial fibrillation (after a 2-week "blanking period") a

97 tients aged 60 years or older with permanent atrial fibrillation (defined as no plan to restore sinus

98 we randomly assigned patients who had early atrial fibrillation (diagnosed <=1 year before enrollmen

99 n Addition to Catheter Ablation to Eliminate Atrial Fibrillation (ERADICATE-AF) trial was an investig

100 (hazard ratio [HR], 5.6 [95% CI, 2.3-13.5]), atrial fibrillation (HR, 2.6 [95% CI, 1.7-3.5]), and lef

101 The major indication was atrial fibrillation (n = 31 [60%]).

102 not undergo surgery (n=25), had a history of atrial fibrillation (n=45), or had no information on the

103 Postoperatively, AKI was associated with atrial fibrillation (P = 0.013) and pneumonia (P = 0.005

104 in older patients (p = 0.019) and those with atrial fibrillation (p = 0.066), lower hematocrit (p = 0

105 Closure vs. Novel Anticoagulation Agents in Atrial Fibrillation (PRAGUE-17) was a multicenter, rando

106 cent structures are frequent in patient with atrial fibrillation (prevalence: 13.5%).

107 ng to rhythm (atrial fibrillation 8.03:1; no atrial fibrillation 5.75:1) and with age, renal function

108 47.3+/-17 years old, having vagal paroxysmal atrial fibrillation 58 (70%) or neurocardiogenic syncope

109 tio varied considerably according to rhythm (atrial fibrillation 8.03:1; no atrial fibrillation 5.75:

110 (Pulsed Fields for Persistent Atrial Fibrillation [PersAFOne]; NCT04170621).

111 Closure vs. Novel Anticoagulation Agents in Atrial Fibrillation [PRAGUE-17]; NCT02426944).

112 luded treatment with antiarrhythmic drugs or atrial fibrillation ablation after randomization.

113 alone in an unselected population undergoing atrial fibrillation ablation with low fibrosis burden.

114 safety outcomes for patients with new onset atrial fibrillation after cardiac surgery who are treate

115 aneous Coronary Intervention), patients with atrial fibrillation and a recent acute coronary syndrome

116 Aspirin vs Aspirin Placebo in Patients With Atrial Fibrillation and Acute Coronary Syndrome and/or P

117 es than usual care among patients with early atrial fibrillation and cardiovascular conditions.

118 Atrial fibrillation and delirium are common consequences

119 34 569 new users of oral anticoagulants with atrial fibrillation and estimated glomerular filtration

120 ents for early-onset coronary heart disease, atrial fibrillation and prostate cancer.

121 In AUGUSTUS, 4614 patients with atrial fibrillation and recent acute coronary syndrome o

122 Among patients with permanent atrial fibrillation and symptoms of heart failure treate

123 etomidine reduces the incidence of new-onset atrial fibrillation and the incidence of delirium.

124 ng, sleep, cerebrovascular disease, frailty, atrial fibrillation and vitamin C).

125 ause stroke among hemodialysis patients with atrial fibrillation are partially mediated by lower use

126 Four cases of (paroxysmal) atrial fibrillation are presented, two cases of sepsis a

127 (after a 2-week "blanking period") and total atrial fibrillation burden (proportion of time in atrial

128 In patients with atrial fibrillation but lower CHA(2)DS(2)-VASc scores, t

129 arrhythmias related to inflammation such as atrial fibrillation can also be expected, in addition to

130 ables to clinical factors improved new-onset atrial fibrillation discrimination in a multivariable lo

131 edical history, and development of new-onset atrial fibrillation during the first four days of ICU ad

132 Improvements in Atrial Fibrillation Effect on Quality-of-Life scores wer

133 on (LAAO) to prevent stroke in patients with atrial fibrillation has been evaluated in 2 randomized t

134 es Registry for Better Informed Treatment of Atrial Fibrillation II Registry from 2013 to 2016, 741 u

135 gle-nucleotide polymorphisms associated with atrial fibrillation in ambulatory studies using a Sequen

136 have demonstrated that catheter ablation for atrial fibrillation in patients with heart failure with

137 er week and who had paroxysmal or persistent atrial fibrillation in sinus rhythm at baseline were ran

138 ow it may impact the way we currently detect Atrial Fibrillation in the general population.

139 ceptibility contributes to risk of new-onset atrial fibrillation in the ICU.

140 5 referral centers for catheter ablation of atrial fibrillation in the Russian Federation, Poland, a

141 High-risk groups of patients with atrial fibrillation include patients with end-stage rena

142 cardiac electrograms during human persistent atrial fibrillation mapping (n=16).

143 become a favourable option in patients with atrial fibrillation not eligible for oral anticoagulatio

144 Grade 3-4 atrial fibrillation occurred in one (1%) patient and gra

145 and may explain the higher vulnerability to atrial fibrillation of obese patients.

146 cs of a contemporary cohort of patients with atrial fibrillation on OAC who underwent cardiac cathete

147 defined as occurrence of postcardiac surgery atrial fibrillation or flutter of at least 30 seconds du

148 44% to 0.59%) for the background population; atrial fibrillation or flutter: 3.44% (95% CI: 3.06% to

149 ort included 55 paroxysmal and 21 persistent atrial fibrillation patients undergoing either RF/PF (40

150 A total of 333 enrolled persistent atrial fibrillation patients underwent ablation.

151 coagulation percentage relative to peers for atrial fibrillation patients with elevated stroke risk (

152 lation may be a novel therapeutic target for atrial fibrillation prevention and treatment.

153 trigger origins in patients with paroxysmal atrial fibrillation receiving catheter ablation.

154 neous coronary intervention in patients with atrial fibrillation receiving oral anticoagulation.

155 ion, there was a significantly lower rate of atrial fibrillation recurrence with catheter cryoballoon

156 Human patients with persistent atrial fibrillation show sixfold lower levels of myocard

157 s is a central pathophysiological feature of atrial fibrillation that also hampers its treatment; the

158 ents with symptomatic, paroxysmal, untreated atrial fibrillation to undergo catheter ablation with a

159 lp with shared decision-making in persistent atrial fibrillation treatment.

160 Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial [CABANA]; NCT00911508).

161 In a real-world registry of patients with atrial fibrillation undergoing cardiac catheterization,

162 nsider the impact of birthweight on incident atrial fibrillation using summary data from the Early Gr

163 of aspirin among patients with both CCS and atrial fibrillation who require anticoagulation.

164 n the CASTLE-AF study (Catheter Ablation for Atrial Fibrillation With Heart Failure) population.

165 (4) ventricular tachycardia (>15 beats); (5) atrial fibrillation with rapid ventricular response; (6)

166 l fibrillation burden (proportion of time in atrial fibrillation) during 6 months of follow-up.

167 ation Versus Antiarrhythmic Drug Therapy for Atrial Fibrillation) trial randomized 2,204 patients wit

168 , coronary heart disease, heart failure, and atrial fibrillation).

169 (coronary heart disease, heart failure, and atrial fibrillation).

170 y dose use were: 1.69 (95% CI 1.54-1.85) for atrial fibrillation, 1.75 (95% CI 1.56-1.97) for heart f

171 In persistent atrial fibrillation, a positive correlation was found be

172 se (CVD), including coronary artery disease, atrial fibrillation, and heart failure, was more prevale

173 d, differs between patients with and without atrial fibrillation, and increases substantially with in

174 sing the 3-incision technique, no history of atrial fibrillation, and ischemic cause.

175 15.50), followed by coronary heart disease, atrial fibrillation, and stroke.

176 d systolic hypertension, with versus without atrial fibrillation, and with versus without diabetes me

177 mise in improving outcomes in heart failure, atrial fibrillation, and, in preclinical studies, certai

178 ed recurrence of any atrial tachyarrhythmia (atrial fibrillation, atrial flutter, or atrial tachycard

179 lysis including age, male gender, paroxysmal atrial fibrillation, basal QTc values, basal heart rate

180 ardiomyopathy characterized by high rates of atrial fibrillation, conduction disease, advanced heart

181 schemic heart disease, aortic valve disease, atrial fibrillation, congenital heart disease, various c

182 associated with heart failure, ischemia, and atrial fibrillation, enhance Na(+) influx, generating a

183 0,258 patients with four arrhythmia classes: atrial fibrillation, general supraventricular tachycardi

184 mmonly used to reduce thromboembolic risk in atrial fibrillation, have been incriminated as probable

185 ing cerebral SVD with large vessel atheroma, atrial fibrillation, heart failure, and heart valve dise

186 mary types of genetic analyses performed for atrial fibrillation, including linkage studies, genome-w

187 econdary stroke prevention for patients with atrial fibrillation, including those with high risk of b

188 anagement of ESKD hemodialysis patients with atrial fibrillation, investigating racial/ethnic dispari

189 asal heart rates, higher rates of paroxysmal atrial fibrillation, lower platelet count.

190 In non-surgical patients with atrial fibrillation, novel oral anticoagulants (NOACs) h

191 en reported, including erectile dysfunction, atrial fibrillation, obstructive sleep apnoea, osteoporo

192 No cases of jaw osteonecrosis, atrial fibrillation, or nonhealing fractures were report

193 ciations with coronary artery disease (CAD), atrial fibrillation, or reduced left ventricular functio

194 of the relationship between birthweight and atrial fibrillation, supporting the growing body of evid

195 Atrial fibrillation, the most common cardiac arrhythmia,

196 nitial treatment for symptomatic, paroxysmal atrial fibrillation, there was a significantly lower rat

197 on; NCT03639597) in patients with paroxysmal atrial fibrillation, this LICU system was evaluated to d

198 , which showed that amongst individuals with atrial fibrillation, those with genetically lower levels

199 opathy, hypertension, myocardial infarction, atrial fibrillation, valvular disease, and revasculariza

200 creases and prolongs spontaneous episodes of atrial fibrillation, whereas atrial-specific overexpress

201 oagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarctio

202 mproved anticoagulation use in patients with atrial fibrillation.

203 for focusing the framework: hypertension and atrial fibrillation.

204 fibrosis is a major contributor to sustained atrial fibrillation.

205 myocardial remodeling that paves the way of atrial fibrillation.

206 bservational associations between height and atrial fibrillation.

207 tion of cardioembolic stroke attributable to atrial fibrillation.

208 of stroke/systemic embolism in patients with atrial fibrillation.

209 en shown to contribute to the development of atrial fibrillation.

210 with increased incidence of ventricular and atrial fibrillation.

211 at may result in an antiarrhythmic effect on atrial fibrillation.

212 f traditional cardiovascular risk factors on atrial fibrillation.

213 luded 56,587 ESKD hemodialysis patients with atrial fibrillation.

214 e patients admitted with ischemic stroke and atrial fibrillation.

215 lmonary vein (PV) isolation in patients with atrial fibrillation.

216 biomarker release, myocardial fibrosis, and atrial fibrillation.

217 ined significantly associated with new-onset atrial fibrillation.

218 ial fibrosis and increases susceptibility to atrial fibrillation.

219 t of persistent and long-standing persistent atrial fibrillation.

220 he range of kidney function in patients with atrial fibrillation.

221 offer therapeutic avenues for patients with atrial fibrillation.

222 or variants associated with ECG measures and atrial fibrillation.

223 irthweight and a large biobank-based GWAS of atrial fibrillation.

224 ulants vs. Warfarin for post Cardiac Surgery Atrial Fibrillation: The NEW-AF Trial.

225 Ablation System for Treatment of Paroxysmal Atrial Fibrillation; NCT03639597) in patients with parox

226 Although transcriptome analysis of human atrial fibroblasts reveals little change after exposure

227 c overexpression of calcitonin prevents both atrial fibrosis and fibrillation.

228 al-specific knockdown of calcitonin promotes atrial fibrosis and increases and prolongs spontaneous e

229 alcitonin receptor signalling in mice causes atrial fibrosis and increases susceptibility to atrial f

230 This study aims to estimate atrial fibrosis from cardiac magnetic resonance scans us

231 Scientific research on atrial fibrosis in atrial fibrillation (AF) has mainly f

232 ur), action potential duration, and reversed atrial fibrosis in diet-induced obese mice as compared w

233 Pathological atrial fibrosis is a major contributor to sustained atri

234 ng cardiac magnetic resonance (CMR)-detected atrial fibrosis plus pulmonary vein isolation (PVI).

235 tic ablation approach targeting CMR-detected atrial fibrosis plus PVI was not more effective than PVI

236 es, NOX2, and PKC-alpha/delta expression and atrial fibrosis were significantly increased in diet-ind

237 source of variability in the measurement of atrial fibrosis.

238 Atrial fibrillation (AF) and atrial flutter (AFL) are associated with both diabetes m

239 l consecutive patients presenting with AF or atrial flutter on DOAC were included.

240 malous bundles, ventricular premature beats, atrial flutter, atrioventricular nodal reentry, and atri

241 drome (in three [18%] patients); and sepsis, atrial flutter, indirect hyperbilirubinaemia, cerebral h

242 atrial tachyarrhythmia (atrial fibrillation, atrial flutter, or atrial tachycardia) between 91 and 36

243 iant patients who present for ablation in AF/atrial flutter, the procedures could be performed withou

244 lower LV systolic function, and reduced left atrial function over long-term follow-up.

245 ntraction (MV A Peak) indicating poorer left atrial function was associated with lower retinal venula

246 c variation, epigenetic gene regulation, and atrial function.

247 anges of contractile proteins such as higher atrial gene expression and lower MYH7/MYH6 ratio correla

248 The extent of atrial interstitial fibrosis, cardiomyocyte myocytolysis

249 Left atrial (LA) dysfunction and stiffness contribute to the

250 investigated left ventricular (LV) and left atrial (LA) pathophysiological changes and their prognos

251 new 2-lead system eliminated the need for an atrial lead.

252 Importantly, in ablation-naive patients, atrial LGE is associated with electrogram fractionation

253 Atrial mass was increased in ZO-1cKO.

254 ally regulates contractility in skeletal and atrial muscle.

255 udy reveals the biological basis for chronic atrial myocardial remodeling that paves the way of atria

256 ivation of Ca(2+) current was 40 to 70 ms in atrial myocytes (depending on holding potential) so this

257 When primary cultures of Pam (0-Cre-cKO/cKO) atrial myocytes (no Cre recombinase, PAM floxed) were tr

258 nt which was found to be absent in tubulated atrial myocytes and ventricular myocytes.

259 Next, we show that the increased SR load in atrial myocytes predisposes these cells to subcellular C

260 ssion of exogenous PAM in Pam (Myh6-cKO/cKO) atrial myocytes produced a dose-dependent rescue of proA

261 cell patch clamping, in vitro tachypacing of atrial myocytes, lucigenin chemiluminescence assay, immu

262 high-density electric mapping, isolation of atrial myocytes, whole-cell patch clamping, in vitro tac

263 iggered calcium waves (TCWs) in isolated dog atrial myocytes.

264 modeling in the left atrium (LA) that begets atrial myopathy and arrhythmias.

265 talized in myocytes, as it was distinct from atrial natriuretic peptide receptor-cGMP-PKG-RyR2 Ser-28

266 the NEP-dependent degradation of vasodilator atrial natriuretic peptide.

267 Patterning of the CCS into atrial node versus ventricular conduction system (VCS) c

268 However, SNA, resting HR, HRV, and atrial (p = 0.03) and ventricular (p = 0.03) proarrhythm

269 vel gene therapy approach in a canine, rapid atrial pacing model of AF, we demonstrate that NADPH oxi

270 patients (77%) with a normal predicted left atrial pressure (grade I diastolic dysfunction) had a me

271 Evaluation of left atrial pressure is frequently required for mechanically

272 ere common among patients with CS, and right atrial pressure was associated with increased mortality

273 usion pressure (a frequent surrogate of left atrial pressure) in this population.

274 (pulmonary capillary wedge pressure - right atrial pressure), LV myocardial stiffness was nearly 30%

275 Impaired right atrial (RA) reservoir strain and elevated estimated RA p

276 The underlying molecular pathways that drive atrial remodeling during cardiac pressure overload are p

277 Sustained AFL causes atrial repolarization changes like those in AF but, unli

278 ion of ID nanodomains has been identified in atrial samples from AF patients.

279 ates or cardiomyocytes, were assessed in 265 atrial samples from patients without or with POAF.

280 The impact of atrial/SAN-selective ablation of Galpha(o) or Galpha(i2)

281 Automatic atrial segmentation achieved a 91% Dice score, compared

282 0.5, a previously established model to study atrial septum defects, which displayed polydactyly or hy

283 s and is the recommended measurement of left atrial size.

284 1 is knocked down specifically in the atria, atrial-specific knockdown of calcitonin promotes atrial

285 ous episodes of atrial fibrillation, whereas atrial-specific overexpression of calcitonin prevents bo

286 One hundred nine human surgical right atrial specimens were evaluated.

287 network was designed to accurately delineate atrial structures including the blood pool, pulmonary ve

288 t was the first documented recurrence of any atrial tachyarrhythmia (atrial fibrillation, atrial flut

289 during 12.9+/-9.4 months, and any documented atrial tachyarrhythmia after the 3-month blanking period

290 lantable cardiac monitoring device to detect atrial tachyarrhythmia.

291 proportion of patients with freedom from AF/atrial tachycardia after a single procedure was 49.2% (9

292 ity of patients, with a high freedom from AF/atrial tachycardia off antiarrhythmic drugs at long-term

293 heart rate (HR) and is often accompanied by atrial tachycardia or atrioventricular (AV) block.

294 mia (atrial fibrillation, atrial flutter, or atrial tachycardia) between 91 and 365 days after cathet

295 flutter, atrioventricular nodal reentry, and atrial tachycardia, treated with conventional ablation (

296 ated from control and AF dogs (kept in AF by atrial tachypacing [600 bpm x 1 week]).

297 : sustained AFL; sustained AF (600 beats/min atrial tachypacing); AF superimposed on an AFL substrate

298 The latter effect is more potent in atrial than ventricular myocytes, and this could be expl

299 Atrial-tissue fibrosis is a central pathophysiological f

300 ta, color Doppler jet/left atrial area, left atrial volume index, left ventricular end-diastolic volu